Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 5
1988 10
1989 10
1990 18
1991 22
1992 14
1993 9
1994 10
1995 6
1996 6
1997 6
1998 7
1999 6
2000 3
2001 4
2002 3
2003 2
2004 1
2005 4
2006 4
2007 5
2008 4
2009 5
2010 12
2011 11
2012 8
2013 14
2014 17
2015 16
2016 17
2017 14
2018 17
2019 17
2020 17
2021 13
2022 16
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

345 results

Results by year

Filters applied: . Clear all
Page 1
Anti-CD37 targeted immunotherapy of B-Cell malignancies.
Payandeh Z, Noori E, Khalesi B, Mard-Soltani M, Abdolalizadeh J, Khalili S. Payandeh Z, et al. Biotechnol Lett. 2018 Dec;40(11-12):1459-1466. doi: 10.1007/s10529-018-2612-6. Epub 2018 Oct 6. Biotechnol Lett. 2018. PMID: 30293139 Review.
CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). ...The anti-CD37 antibodies as one of the most successful therapeutics against CD37 are introduced and the clinical outcomes of their exploitation are explaine …
CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). ...The anti-CD37 antibodie …
CD37 expression in follicular lymphoma.
Yoshimura T, Miyoshi H, Shimono J, Nakashima K, Takeuchi M, Yanagida E, Yamada K, Shimasaki Y, Moritsubo M, Furuta T, Kohno K, Ohshima K. Yoshimura T, et al. Ann Hematol. 2022 May;101(5):1067-1075. doi: 10.1007/s00277-022-04785-z. Epub 2022 Feb 16. Ann Hematol. 2022. PMID: 35171311
CD37 is a tetraspanin protein expressed in various B-cell lymphomas that mediates tumor survival signaling. ...One hundred cases (100/167, 60.0%) were categorized as CD37-positive, and 67 cases were CD37-negative. In cases with high Follicular Lymphoma Intern …
CD37 is a tetraspanin protein expressed in various B-cell lymphomas that mediates tumor survival signaling. ...One hundred cases (100 …
CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies.
Bobrowicz M, Kubacz M, Slusarczyk A, Winiarska M. Bobrowicz M, et al. Int J Mol Sci. 2020 Dec 15;21(24):9531. doi: 10.3390/ijms21249531. Int J Mol Sci. 2020. PMID: 33333768 Free PMC article. Review.
CD37 is a tetraspanin expressed prominently on the surface of B cells. ...In this review, we aimed to provide an extensive overview of the function of CD37 in B cell malignancies, providing a comprehensive view of recent therapeutic advances targeting CD37 an …
CD37 is a tetraspanin expressed prominently on the surface of B cells. ...In this review, we aimed to provide an extensive overview o …
Anti-CD37 antibodies for chronic lymphocytic leukemia.
Robak T, Robak P. Robak T, et al. Expert Opin Biol Ther. 2014 May;14(5):651-61. doi: 10.1517/14712598.2014.890182. Epub 2014 Feb 20. Expert Opin Biol Ther. 2014. PMID: 24555705 Review.
EXPERT OPINION: CD37 may offer advantages over CD20 as a target for CLL cells. It is selectively expressed on normal mature B cells and by most B-cell malignancies. Anti-CD37 antibodies may be useful for patients resistant or refractory to anti-CD20 mAb therapy or r …
EXPERT OPINION: CD37 may offer advantages over CD20 as a target for CLL cells. It is selectively expressed on normal mature B cells a …
Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies.
Witkowska M, Smolewski P, Robak T. Witkowska M, et al. Expert Opin Investig Drugs. 2018 Feb;27(2):171-177. doi: 10.1080/13543784.2018.1427730. Epub 2018 Jan 15. Expert Opin Investig Drugs. 2018. PMID: 29323537 Review.
Currently, novel agents targeting specific molecules on the surface of lymphoma cells, such as anti-CD37 antibodies, are under considerable investigation. Here we report on anti-CD37 targeting for the treatment of patients with B-cell NHL. AREAS COVERED: CD37 …
Currently, novel agents targeting specific molecules on the surface of lymphoma cells, such as anti-CD37 antibodies, are under consid …
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma.
Golubovskaya V, Zhou H, Li F, Valentine M, Sun J, Berahovich R, Xu S, Quintanilla M, Ma MC, Sienkiewicz J, Huang Y, Wu L. Golubovskaya V, et al. Cancers (Basel). 2021 Feb 26;13(5):981. doi: 10.3390/cancers13050981. Cancers (Basel). 2021. PMID: 33652767 Free PMC article.
The goal of this study was to target lymphoma with novel CD37, humanized CD37, and bi-specific humanized CD37-CD19 CAR-T cells. ...The mouse and humanized CD37-CAR-T cells specifically killed Raji and CHO-CD37 cells and secreted IFN-gamma. ...
The goal of this study was to target lymphoma with novel CD37, humanized CD37, and bi-specific humanized CD37-CD19 CAR- …
IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma.
Elfrink S, Ter Beest M, Janssen L, Baltissen MP, Jansen PWTC, Kenyon AN, Steen RM, de Windt D, Hagemann PM, Hess C, van Spronsen DJ, Hoevenaars B, van der Spek E, Xu-Monette ZY, Young KH, Kaffa C, Bervoets S, van Heek J, Hesius E, de Winde CM, Vermeulen M, van den Brand M, Scheijen B, van Spriel AB. Elfrink S, et al. Blood Adv. 2022 Apr 12;6(7):2254-2266. doi: 10.1182/bloodadvances.2021004366. Blood Adv. 2022. PMID: 35086136 Free PMC article.
No differences were observed in DNA methylation within the CD37 promoter region between CD37-positive and CD37-negative primary DLBCL patient samples. On the contrary, CD37-negative DLBCL cells specifically lacked CD37 promoter activity, suggest …
No differences were observed in DNA methylation within the CD37 promoter region between CD37-positive and CD37-negative …
Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37.
Peeters R, Cuenca-Escalona J, Zaal EA, Hoekstra AT, Balvert ACG, Vidal-Manrique M, Blomberg N, van Deventer SJ, Stienstra R, Jellusova J, Giera M, Hannibal L, Spiekerkoetter U, Ter Beest M, Berkers CR, van Spriel AB. Peeters R, et al. Nat Commun. 2022 Sep 13;13(1):5371. doi: 10.1038/s41467-022-33138-7. Nat Commun. 2022. PMID: 36100608 Free PMC article.
Furthermore, CD37-negative lymphomas selectively deplete palmitate from serum in mouse studies. Mechanistically, CD37 inhibits the FA transporter FATP1 through molecular interaction. ...
Furthermore, CD37-negative lymphomas selectively deplete palmitate from serum in mouse studies. Mechanistically, CD37 inhibits …
CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia.
Zhang Q, Han Q, Zi J, Song C, Ge Z. Zhang Q, et al. Biosci Rep. 2020 May 29;40(5):BSR20200008. doi: 10.1042/BSR20200008. Biosci Rep. 2020. PMID: 32400873 Free PMC article.
Patients with high CD37 expression had shorter overall survival (OS) and disease-free survival (DFS). ...CONCLUSION: Our study described systematical expression profiles and the prognostic values of CD37 in AML; our data suggested CD37 might be novel therapeu …
Patients with high CD37 expression had shorter overall survival (OS) and disease-free survival (DFS). ...CONCLUSION: Our study descri …
345 results